TL;DR
- 1.Thymulin peaks in childhood, starts falling in your 20s, and becomes undetectable by standard bioassay in most people after 60. It is the only thymic hormone made exclusively in the thymus.
- 2.Thymulin requires zinc to be active. Many people over 60 still produce some thymulin but are zinc-deficient, so the peptide circulates as inactive apothymulin. Correcting zinc is the first and most evidence-backed step.
- 3.Research by Eugenio Mocchegiani and colleagues at INRCA in Ancona, Italy showed zinc supplementation in zinc-deficient elderly subjects partially restored detectable active thymulin activity.
- 4.Exogenous thymulin is available as a research peptide and also used in zinc-thymulin formulas for hair loss. No controlled human trials on immune restoration have been completed. Human dosing is not established.
- 5.Your HLA type, IL-6 promoter variants, and FOXO3 longevity gene all predict how fast your thymus ages and how effective whatever thymulin you have left actually is at training T-cells.
Your immune system peaked at 12. That is not a metaphor. At that age, your thymus was at full volume and churning out thymulin, the signal your body uses to train every T-cell it produces. By your late 40s, most of that output is gone. By 60, serum thymulin falls below detection in the majority of people by standard bioassay. The immune education system your body was born with has effectively shut down.
The approximate age at which serum thymulin becomes undetectable by standard rosette-inhibition bioassay in most subjects, based on lifespan age-titration studies published in the immunology literature.
Thymulin (also called FTS, from the French facteur thymique serique, or serum thymic factor) is a 9-amino-acid peptide produced exclusively by the thymic epithelial cells lining the interior of your thymus. It is the only thymic hormone made solely within the thymus itself. When the thymus shrinks with age, thymulin output falls. When output falls, T-cell education degrades. That cascade is the mechanistic core of what immunologists call immunosenescence, the slow collapse of immune function after midlife.
This is not an obscure or newly characterized protein. Jean-Francois Bach and Mireille Dardenne at the Institut Pasteur in Paris spent two decades characterizing thymulin, publishing foundational research starting in the early 1970s. The 50-plus years of follow-on work since then is more than most peptides discussed in the longevity space will ever accumulate. What is odd is how rarely thymulin shows up in mainstream discussions of immune aging, even as its cousin Thymosin Alpha-1 gets significant clinic attention. More on why that gap exists later.
Think of your thymus as a military training academy for immune cells. Every T-cell your bone marrow produces has to pass through this academy before it can fight. Thymulin is the curriculum. It is the set of signals that teaches each T-cell what to attack and what to leave alone. When the academy closes, no new soldiers get properly trained. The ones already in service keep working for a while, but the force gets thinner and less adaptable every decade. That is immune aging, stripped of the jargon.
How Fast Does Thymulin Actually Decline With Age?
Faster than most immune markers, and earlier than most people expect. A published lifespan age-titration study (listed in PubMed as "Distribution of age-related thymulin titres in normal subjects through the course of life") measured serum thymulin activity from newborns through elderly subjects. The decline curve is striking enough that it has been described as one of the cleanest biological markers of thymic aging available.
Thymulin activity peaks in early childhood and again around puberty. It starts declining through the 20s and 30s as thymic involution, the progressive replacement of active thymic tissue with fat, gets underway. By the mid-40s, detectable active thymulin has dropped to a fraction of peak levels. By age 60, most subjects in cross-sectional studies show undetectable levels by the rosette-inhibition bioassay used to measure active, zinc-bound thymulin.
| Age Group | Relative Thymulin Activity | What Is Happening |
|---|---|---|
| Birth to age 6 | Rising | Thymus growing rapidly, thymulin output climbing |
| Age 6 to 12 | Peak | Maximum thymic volume and maximum thymulin output |
| Age 20 to 35 | Declining | Thymic involution begins, fat replaces active tissue |
| Age 40 to 55 | Low but detectable | Most thymic tissue replaced, residual output only |
| After age 60 | Undetectable in most subjects | Standard bioassay finds zero active thymulin; some inactive form may remain |
There is an important nuance here. "Undetectable by bioassay" does not necessarily mean zero thymulin is produced. It means active, zinc-bound thymulin has dropped below the assay detection threshold. Some residual peptide may circulate in an inactive form. This distinction is crucial for understanding what can be done about it.
The progressive decline of serum thymulin with age parallels the involution of the thymus and constitutes one of the most reliable markers of thymic aging. Its loss precedes many of the functional immune deficits seen in elderly subjects by years to decades, making it a valuable early indicator of immune aging trajectory.
Review of Thymic Peptides and Hormones from Properties to Clinical Application, Springer, 2024
The Zinc Connection Most Thymulin Guides Skip Over
Here is the part that changes the picture meaningfully. Thymulin is biologically inactive without zinc. The peptide circulates in two forms: active thymulin (zinc-bound) and apothymulin (zinc-free). Only the zinc-bound form can engage thymulin receptors on T-cells and trigger the differentiation signals that define thymulin's role.
Zinc deficiency is extremely common in people over 60. Absorption efficiency drops with age, dietary intake often declines, and competition from other minerals increases. Research by Eugenio Mocchegiani and colleagues at INRCA in Ancona, Italy found that in elderly subjects who showed undetectable active thymulin by bioassay, zinc supplementation partially restored detectable thymulin activity. Those subjects still had some thymulin peptide in circulation, but it was traveling as inactive apothymulin. Adding zinc reactivated a portion of it.
The restoration was not dramatic. The studies did not show a return to childhood levels. But they did establish that "undetectable" sometimes means "the cofactor is missing" rather than "the peptide is gone." That is a clinically important distinction because the intervention for one of those scenarios (zinc supplementation) is cheap, safe, and widely available.
Active Thymulin (Zinc-Bound)
Biologically functional. Binds thymulin receptors on T-cells. Directs thymocyte differentiation into mature T-cell subtypes (CD4+, CD8+). This is the form standard bioassays detect and the form that actually does the work.
Apothymulin (Zinc-Free)
Biologically inactive. Circulates without receptor activity. Cannot train T-cells. Not detected by standard rosette-inhibition bioassay. Present in some elderly subjects who test at zero, meaning the peptide is there but the switch is off.
Before assuming complete thymulin failure, checking zinc status is sensible. Serum zinc below 70 mcg/dL in an adult is deficient by most clinical reference ranges. Correcting zinc through supplementation (typically 15 to 30 mg elemental zinc daily, often as zinc bisglycinate or zinc picolinate for absorption) is the most evidence-backed single intervention in thymic aging. It does not restore the thymus to age-12 output, but it may recover meaningful thymulin activity that zinc deficiency was suppressing.
What Happens to Your Immune System When Thymulin Goes to Zero
T-cell production in the thymus does not completely stop when thymulin vanishes. The thymus still generates some T-cells even in its atrophied state. But the quality and variety of the output degrades. Without adequate thymulin signaling, fewer thymocytes (immature T-cells) successfully acquire the surface markers that define functional T-cell identity, and more are deleted as non-functional or potentially self-reactive.
The downstream effects accumulate over years. Fewer naive T-cells enter circulation. The ones that do carry a narrower receptor repertoire, less capable of recognizing novel pathogens. Regulatory T-cell balance shifts. Cancer immune surveillance weakens. Autoimmune risk increases paradoxically, as immune regulation degrades even while raw immune output falls. The very thing designed to tell your immune system what not to attack becomes less reliable as the machinery that trained it shuts down.
The estimated reduction in functional thymic tissue volume by age 70, based on imaging studies tracking the ratio of active thymic tissue to adipose replacement across age groups from childhood through late adulthood.
A 2024 review article in the Springer journal covering thymic peptide research surveyed 50 years of accumulated evidence and described this pattern across multiple clinical populations, including increased infection susceptibility, elevated cancer incidence, and altered inflammatory tone, all consistent with the thymulin production timeline. The same review highlighted the unusual position thymulin occupies: well-characterized for decades, with a clear biological role, but without completed controlled human trials for supplementation.
This is not hypothetical biology. The elderly immune phenotype, more infections, slower recovery, higher cancer incidence, increased autoimmune activity, is the observable clinical expression of what happens when a lifetime of thymulin-guided T-cell education ends and is not replaced. A 2018 study published on ScienceDirect specifically demonstrated that thymulin treatment attenuated inflammatory pain in animal models, opening a second research direction around thymulin's analgesic and anti-inflammatory properties beyond its thymic role. That work confirmed thymulin receptors exist outside the thymus, which complicates and enriches the picture of what restoring levels might accomplish.
Three Approaches to Thymulin Restoration (Ranked by Evidence)
1. Zinc Supplementation
The most evidence-backed and immediately practical approach, covered above. Corrects the cofactor deficiency that can suppress whatever thymulin is still being produced. Does not rebuild thymic tissue. Does not restore production to youthful capacity. But in zinc-deficient elderly subjects, the partial recovery of active thymulin from the Mocchegiani group's work is real and replicated.
2. Exogenous Thymulin Peptide
Available from research peptide suppliers as an injectable nonapeptide. Research dosing in animal studies ranged widely, often in nanogram-per-kilogram ranges far below what most peptide protocols use. Human translation is genuinely unclear. No controlled human trials on exogenous thymulin for immune restoration have been published with outcome data as of 2026. Compounding clinics offering thymulin typically use doses of 200 to 500 mcg subcutaneous, sometimes in cycles, but these numbers are empirical rather than trial-validated. The regulatory status in the US places thymulin as a research peptide without FDA approval or compounding eligibility under current rules.
3. Zinc-Thymulin Complex for Hair Loss: A Separate Application
This is worth knowing because many people first encounter thymulin through hair loss clinics rather than immunology circles. Thymulin receptors are expressed on hair follicle dermal papilla cells. Early research and a USPTO patent on "thymulin-like peptides for pain-relieving medicines" established that the peptide has activity outside the thymus. Applied to hair loss, zinc-thymulin formulas, delivered topically or by intradermal injection, have been offered by compounding pharmacies and clinics as an androgenic alopecia intervention. The mechanism operates through hair follicle survival and cycling, completely separate from T-cell education. It is mentioned here because it is a real and growing application, not because it overlaps with the immune aging use case.
Why Your HLA Type and FOXO3 Gene Change What Thymulin Does For You
Two people can have identical serum thymulin levels and very different immune outcomes, because the downstream effectiveness of thymulin-guided T-cell education depends on genetics in ways that thymulin levels alone do not capture.
Your HLA (human leukocyte antigen) variants determine which peptide fragments your educated T-cells can recognize and present when they encounter a pathogen or abnormal cell. HLA determines the specificity of what thymulin-trained T-cells can actually detect. Narrow HLA coverage means that even normal thymulin levels produce a less diverse defense. This is why immune aging is not just about how much thymulin you have, but about whether the T-cells it trained can see the threats you actually face.
IL-6 promoter variants that drive chronically elevated baseline inflammation are relevant here too. High IL-6 environments are hostile to thymic epithelial cells, the very cells that make thymulin. If your genetics predispose you to elevated inflammatory tone, your thymic aging likely started earlier and ran faster than the population average. The immune aging curve described above represents an average. Your curve may be 5 to 10 years ahead of it.
The FOXO3 longevity gene is perhaps the most interesting angle. FOXO3 variants associated with centenarian status in multiple independent population studies consistently show preserved immune function at late ages, including evidence of slower thymic involution. Carriers of longevity-associated FOXO3 alleles may retain detectable thymulin past the typical 60-year detection threshold. You can read about how peptide response shifts after 50 including how aging-related genetic variants change your protocol priorities. You can also explore Epithalon and telomere length research, which comes from the same Russian thymic peptide research tradition as thymulin and shows similar longevity-genetics interactions.
For a broader framework on how immune genetics affect peptide choices, see our complete guide to Thymosin Alpha-1 dosage and immune modulation, which covers overlapping HLA, IFNG, and IL-6 variants in depth. And if you are building a full longevity stack, our best peptides for anti-aging in 2026 overview covers where thymulin fits relative to Epithalon, GHK-Cu, and SS-31.
The PeptidesDNA report covers HLA immune markers, FOXO3 variants, IL-6 promoter, and zinc transporter genes most relevant to thymic aging and peptide response. Upload your existing 23andMe or AncestryDNA file at /upload or order a saliva kit at /order-kit to get your full immune aging panel. You can also view the full thymulin peptide profile including sourcing considerations and mechanism summary.
Verdict: Thymulin is the most upstream immune aging peptide in the research pipeline, but zinc is where you start. The 50-year body of evidence linking thymulin decline to immune aging is real. The evidence that exogenous thymulin in humans restores measurable immune function is not there yet in controlled form. Fix zinc deficiency first, assess your immune genetics, and consider Thymosin Alpha-1 as the near-term bridge with actual human trial data while thymulin research matures. If you are building this stack, knowing your HLA type, FOXO3 status, and IL-6 variants is not optional: they determine whether the T-cells thymulin educates can actually do the job they were trained for. Test your immune genetics at /upload or order a kit.
Your DNA shapes how you respond to the peptides discussed above.
A personalized report scores 25+ peptides against your unique genetic profile — including the ones covered in this article.
Frequently asked questions
What does thymulin actually do in the body?
Thymulin is a hormone produced by thymic epithelial cells that guides the maturation of immature T-cells (thymocytes) into functional immune cells. It induces expression of T-cell surface markers like CD4 and CD8 that define T-cell identity and function. Without adequate thymulin, thymocytes cannot complete their education inside the thymus and either fail to become functional T-cells or are deleted. Thymulin also has anti-inflammatory and analgesic properties shown in animal research, suggesting it acts in tissues outside the thymus as well.
Why does thymulin go to zero as you age?
Thymulin is made only by thymic epithelial cells, and the thymus undergoes a process called involution starting in early adulthood. Active thymic tissue is progressively replaced by adipose (fat) tissue, shrinking the population of thymulin-producing cells. By age 60, most people have so little functional thymic tissue remaining that thymulin output falls below detection by standard bioassay. The process is driven by hormonal changes, inflammatory signals, and oxidative stress on thymic cells over decades.
Can zinc supplementation restore thymulin?
Partially, in zinc-deficient individuals. Thymulin requires zinc to be biologically active. Without zinc it circulates as inactive apothymulin, which standard tests cannot detect. Research by Mocchegiani and colleagues found that zinc supplementation in zinc-deficient elderly subjects restored some detectable active thymulin. This does not rebuild the thymus or restore production to youthful levels, but it may recover meaningful activity that zinc deficiency was suppressing. Testing serum zinc before assuming complete thymulin failure is sensible.
What is the difference between thymulin and Thymosin Alpha-1?
Thymulin acts upstream in the T-cell maturation process inside the thymus, training thymocytes into functional T-cells. Thymosin Alpha-1 is a 28-amino-acid peptide that acts on already-mature T-cells and dendritic cells to modulate their activity and bias immune response toward the Th1 arm. Thymosin Alpha-1 has over 30 completed controlled trials in humans and is approved in 35 countries. Thymulin has no completed controlled human trials for immune restoration. In practical terms: Thymosin Alpha-1 has far more human evidence. Thymulin is further upstream biologically but further behind on clinical validation.
What is zinc-thymulin and why is it used for hair loss?
Zinc-thymulin refers to the active zinc-bound form of the thymulin peptide. Hair follicle dermal papilla cells express thymulin receptors, and early research found that thymulin signaling promotes follicle survival and hair cycle progression. Compounding clinics have developed zinc-thymulin formulas applied topically or by intradermal injection as an androgenic alopecia treatment. This hair loss application operates through follicle biology rather than T-cell education. The two applications are mechanistically separate, though both rely on the same peptide in its active zinc-bound form.
Is thymulin available as a research peptide and what do clinics dose it at?
Thymulin is available from research peptide suppliers as an injectable nonapeptide. It does not have FDA approval for any indication and is not currently eligible for compounding under US pharmacy rules, placing it in research-peptide-only status. Clinics that use it tend to dose at 200 to 500 mcg subcutaneous, sometimes weekly or in monthly cycles, but these are empirical protocols without human trial validation behind them. Animal research used nanogram-per-kilogram dosing ranges that do not translate cleanly to human protocols. Anyone using thymulin should treat it as an investigational compound.
How do genetics affect thymulin response?
Your HLA type determines the breadth of what thymulin-educated T-cells can recognize. Narrow HLA coverage limits immune effectiveness even when thymulin levels are adequate. IL-6 promoter variants that drive chronic inflammation accelerate thymic involution, meaning your thymulin timeline may be faster than average. FOXO3 longevity variants are associated with slower thymic aging and later thymulin decline. Zinc transporter gene variants affect how much zinc reaches thymic epithelial cells, influencing whether produced thymulin stays in active or inactive form.
This article is for informational and educational purposes only. It is not medical advice and does not diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before starting any peptide protocol. Individual results vary.